These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38750400)

  • 1. Impact on Quality during In-Use Preparation of an Antibody Drug Conjugate with Eight Different Closed System Transfer Device Brands.
    Sorret L; Tan WH; Voss S; Favrod P; Chalus P; Winzer M
    AAPS J; 2024 May; 26(3):61. PubMed ID: 38750400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of Holdup Volume and Transient Contact Compatibility of Closed System Transfer Devices for a Reconstituted Lyophilized Drug Product.
    Kagdi R; Le K; Doucet D; Ludlow J; Rinella JV
    J Pharm Sci; 2020 Nov; 109(11):3504-3511. PubMed ID: 32771346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming Challenges of Implementing Closed System Transfer Device Clinical In-Use Compatibility Testing for Drug Development of Antibody Drug Conjugates.
    Petoskey F; Kwok SC; Jackson W; Jiang S
    J Pharm Sci; 2020 Jan; 109(1):761-768. PubMed ID: 31376374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges of Using Closed System Transfer Devices With Biological Drug Products: An Industry Perspective.
    Sreedhara A; Zamiri C; Goswami S; Weiser S; Cram M; Christian TR; Jagannathan B
    J Pharm Sci; 2020 Jan; 109(1):22-29. PubMed ID: 31697946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Different Quality-Relevant Aspects of Closed System Transfer Devices (CSTDs).
    Besheer A; Mahler HC; Matter-Schwald A; Barrenechea SM; Vogt M; Chalus P; Heymes P; Pillow T; Kirste A; Favrod P; Joerg S; Mathaes R
    Pharm Res; 2020 Apr; 37(4):81. PubMed ID: 32274594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Silicone from Closed System Transfer Devices and its Migration into Pharmaceutical Drug Products.
    Wozniewski M; Besheer A; Sediq AS; Huwyler J; Mahler HC; Levet V
    J Pharm Sci; 2024 Feb; 113(2):419-426. PubMed ID: 37989442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Approach to Evaluating Closed System Drug-Transfer Devices During Drug Product Development.
    Patke S; Gaillat EN; Calero-Rubio C; Gooding TB; Audat H; Leman M; Filipe V; Saluja A
    J Pharm Sci; 2022 May; 111(5):1325-1334. PubMed ID: 34958824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Closed System Transfer Device (CSTD) Handling Procedure for Low-Transfer-Volume Dose Preparation of Biologic Drug Products.
    Grzincic EM; Parikh T; Hong C; Rabiah NI; Yi L; Gupta S
    J Pharm Sci; 2024 Jun; 113(6):1523-1535. PubMed ID: 38142969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Industry Perspective on Compatibility Assessment of Closed System Drug-Transfer Devices for Biologics.
    Besheer A; Burton L; Galas RJ; Gokhale K; Goldbach P; Hu Q; Mathews L; Muthurania K; Narasimhan C; Singh SN; Stokes ESE; Weiser S; Zamiri C; Zhou S
    J Pharm Sci; 2021 Feb; 110(2):610-614. PubMed ID: 33127425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of unintended volume loss of six closed system transfer devices.
    Kulju S; McIntosh BA; Fuller HJ; Arnold T; Gunnar W
    J Oncol Pharm Pract; 2020 Jul; 26(5):1134-1140. PubMed ID: 31775580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing a flowchart to evaluate the use of Closed System Drug-Transfer Devices with monoclonal antibodies: Focus on the clinical trial setting.
    Simal I; Bauters T; Paepens C; Clottens N; Ramaut P; Kestens E
    J Oncol Pharm Pract; 2023 Dec; 29(8):2014-2022. PubMed ID: 37680124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs).
    Sumikawa S; Yakushijin Y; Aogi K; Yano T; Hiroki ; Hashimoto ; Tsukui C; Noguchi T; Shiraishi T; Horikawa Y; Yasuoka Y; Tanaka A; Hidaka N; Tanaka M
    Sci Rep; 2022 Jan; 12(1):139. PubMed ID: 34996936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff.
    Gurusamy KS; Best LM; Tanguay C; Lennan E; Korva M; Bussières JF
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012860. PubMed ID: 29582940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of studies examining microbial contamination of vials used for preparations done with closed-system drug transfer devices.
    Soubieux A; Tanguay C; Bussières JF
    Eur J Hosp Pharm; 2021 Mar; 28(2):65-70. PubMed ID: 33608432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Industry Perspective on the Challenges of Using Closed System Transfer Devices with Biologics and Communication Guidance to Healthcare Professionals.
    Gopalrathnam G; Christian TR; Jagannathan B; Petoskey F; Kühnle B; Weiser S; Kagdi R; Saluja S; Bhattacharyya A; Burton L; Zamiri C; Hanley K
    J Pharm Sci; 2021 Jun; 110(6):2329-2335. PubMed ID: 33617871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs.
    Bartel SB; Tyler TG; Power LA
    Am J Health Syst Pharm; 2018 Feb; 75(4):199-211. PubMed ID: 29339374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Closed-system transfer device use with oncology biologics: A survey of Canadian healthcare practitioners.
    Khaira M; Guy AL
    J Oncol Pharm Pract; 2022 Jun; 28(4):805-815. PubMed ID: 34000919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques.
    Harrison BR; Peters BG; Bing MR
    Am J Health Syst Pharm; 2006 Sep; 63(18):1736-44. PubMed ID: 16960258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and reduction of hazardous drug surface contamination through the use of a novel closed-system transfer device coupled with a point-of-care hazardous drug detection system.
    Brechtelsbauer E
    Am J Health Syst Pharm; 2023 Mar; 80(7):435-444. PubMed ID: 36370411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic Investigation on Grinding-Induced Subvisible Particle Formation during Mixing and Filling of Monoclonal Antibody Formulations.
    Gikanga B; Hui A; Maa YF
    PDA J Pharm Sci Technol; 2018; 72(2):117-133. PubMed ID: 29030532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.